Last week MedImmune Ltd., the biotech arm of AstraZeneca plc (NYSE: AZN), announced two placements for its investigational compound, MEDI4736. The first announcement was with Juno Therapeutics Inc. (NASDAQ: JUNO), which signed an non-exclusive agreement to test its own investigational CD19-directed chimeric antigen receptor (CAR) T cell candidates with MedImmune’s programmed cell death ligand 1 (PD-L1) immune check point inhibitor, MEDI4736, aiming for a combination therapy. No financial details were disclosed on that, but the next day, MedImmune announced a deal with a Swiss subsidiary of Celgene Corp. (NASDAQ: CELG), worth an upfront payment of $450 million from Celgene, to investigate MEDI4736’s adequacy as a combination therapy with Celgene’s pipeline. Other assets could become part of this investigation.
MedImmune Parcels Out an Investgational Blood Cancer Candidate
by Lisa Phillips | Apr 20, 2015 4:13 pm | Biotechnology
Categories
- Ambulatory Surgery Centers
- Behavioral Health Care
- Biotechnology
- CDMO
- CRO
- eHealth
- Healthcare M&A News Leads
- Healthcare Market Updates
- Healthcare Staffing
- Home Health & Hospice
- Hospitals
- Laboratories, MRI & Dialysis
- Long-Term Care
- Managed Care
- Medical Devices
- Medical Office Buildings
- Occupational Health
- Other Services
- Pharmaceuticals
- Physician Medical Groups
- Private Equity
- Rehabilitation
- SPAC
- Specialty Pharmacies
- Uncategorized
- Urgent Care Centers